NVSEF Stock DD Novartis AG 08/07/2014 05:31:51

New Post Public Reply Private Reply Replies (0) Message Board

Aug 7, 2014 at 6:31 AM

NVSEF Novartis AG $NVSEF Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=NVSEF&am...mp;yt0=Go!

Last Updated: 08/07/2014 05:31:47

Current Price and Quotes
Last Price 86.32
Previous Close 87.2332 Open 85.96
Daily Range N/A - 86.32 52wk Range 72.56 - 91.68
Volume 769 Dividend N/A
Average Vol (3m) 25,305 Yield N/A

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 58,831,000 57,561,000 59,375,000 51,561,000
Cost of Revenue 19,608,000 18,756,000 18,983,000 14,488,000
Gross Profit 39,223,000 38,805,000 40,392,000 37,073,000
Operating Expenses

Research and Development 9,852,000 9,332,000 9,583,000 9,070,000
Sales, General and Admin. 18,461,000 18,280,000 20,029,000 16,477,000
Non-Recurring Items - - - -
Other - - - -
Operating Income 10,910,000 11,193,000 10,780,000 11,526,000
Income From Continuing Operations

Add'l Income/Expense Items (92,000) (96,000) (2,000) 64,000
Earnings Before Interest and Tax 11,418,000 11,649,000 11,306,000 12,394,000
Interest Expense 683,000 724,000 751,000 692,000
Earnings Before Tax 10,735,000 10,925,000 10,555,000 11,702,000
Income Tax 1,443,000 1,542,000 1,483,000 1,733,000
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary 600,000 552,000 528,000 804,000
Net Income Cont. Operations 9,892,000 9,935,000 9,600,000 10,773,000
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 9,292,000 9,383,000 9,072,000 9,969,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 9,292,000 9,383,000 9,072,000 9,969,000

Recent News

Aug 6, 2014 Mark D. Hanson to Join Evercore as a Senior Managing Director in Its Healthcare Group
Aug 5, 2014 Novartis announces NEJM publication of two phase III studies demonstrating high efficacy of investigational new drug secukinumab (AIN457) in psoriasis patients
Aug 5, 2014 Boyden's Leadership Series Features Novartis' Ranjit Shahani
Aug 1, 2014 ICON: Pfizer and Roche Join ADDPLAN DF Consortium
Jul 31, 2014 Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
Jul 31, 2014 Research and Markets: Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
Jul 31, 2014 TB Alliance Names Elana Robertson Senior Vice President, Market Access
Jul 31, 2014 KAE609 shows promise as next generation treatment for malaria
Jul 29, 2014 Novartis vaccine Bexsero(R) sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B (Thomson Reu
Jul 28, 2014 Alcon's Simbrinza(R) approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease (Thomson Reu

1
2
3
4
5
6
7
8
next >
last >>